Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Auer, R. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Auer, R. N.
NEUROLOGY 1998;51:S39-S43
© 1998 American Academy of Neurology

Insulin, blood glucose levels, and ischemic brain damage

Roland N. Auer, MD, PhD, FRCPC

From the Department of Pathology, University of Calgary, Alberta, Canada.

Address correspondence and reprint requests to Dr. Roland N. Auer, Department of Pathology, Faculty of Medicine, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta, Canada T2N 4N1.

Abstract.

Intensive efforts are presently directed toward developing pharmacologic therapy to protect the ischemic brain. Preclinical data from animal models indicate that insulin, already available for human use, may reduce damage in both global and focal ischemia. Two kinds of mechanisms may be involved: one in which insulin interacts directly with brain tissue and one in which insulin acts indirectly by reducing peripheral blood glucose levels. Animal data indicate that part of the former, direct mechanism is mediated by insulin-like growth factor-1 receptors. The direct effect appears to predominate in global ischemia. In focal ischemia, unlike global ischemia, the effect of insulin is predominantly via peripheral hypoglycemia, because neuroprotection is largely annulled by co-administration of glucose. The two clinical counterparts of global and focal ischemic models are, respectively, cardiac arrest encephalopathy and focal ischemic stroke. Insulin use in both of these clinical situations could be evaluated in clinical trials that attempt to reduce ischemic brain damage, because insulin has a long and safe history of human use in diabetes treatment.




This article has been cited by other articles:


Home page
CirculationHome page
R. W. Neumar, J. P. Nolan, C. Adrie, M. Aibiki, R. A. Berg, B. W. Bottiger, C. Callaway, R. S.B. Clark, R. G. Geocadin, E. C. Jauch, et al.
Post-Cardiac Arrest Syndrome: Epidemiology, Pathophysiology, Treatment, and Prognostication A Consensus Statement From the International Liaison Committee on Resuscitation (American Heart Association, Australian and New Zealand Council on Resuscitation, European Resuscitation Council, Heart and Stroke Foundation of Canada, InterAmerican Heart Foundation, Resuscitation Council of Asia, and the Resuscitation Council of Southern Africa); the American Heart Association Emergency Cardiovascular Care Committee; the Council on Cardiovascular Surgery and Anesthesia; the Council on Cardiopulmonary, Perioperative, and Critical Care; the Council on Clinical Cardiology; and the Stroke Council
Circulation, December 2, 2008; 118(23): 2452 - 2483.
[Full Text] [PDF]


Home page
StrokeHome page
M. T. McCormick, K. W. Muir, C. S. Gray, and M. R. Walters
Management of Hyperglycemia in Acute Stroke: How, When, and for Whom?
Stroke, July 1, 2008; 39(7): 2177 - 2185.
[Full Text] [PDF]


Home page
Anesth. Analg.Home page
D. Nagamizo, S. Tsuruta, M. Matsumoto, H. Matayoshi, A. Yamashita, and T. Sakabe
Tight Glycemic Control by Insulin, Started in the Preischemic, but Not Postischemic, Period, Protects Against Ischemic Spinal Cord Injury in Rabbits
Anesth. Analg., November 1, 2007; 105(5): 1397 - 1403.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
W. N. Kernan, C. M. Viscoli, S. E. Inzucchi, L. M. Brass, D. M. Bravata, G. I. Shulman, and J. C. McVeety
Prevalence of Abnormal Glucose Tolerance Following a Transient Ischemic Attack or Ischemic Stroke
Arch Intern Med, January 24, 2005; 165(2): 227 - 233.
[Abstract] [Full Text] [PDF]


Home page
Br. J. Ophthalmol.Home page
R J Casson, J P M Wood, and N N Osborne
Hypoglycaemia exacerbates ischaemic retinal injury in rats
Br. J. Ophthalmol., June 1, 2004; 88(6): 816 - 820.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
T. A. Baird, M. W. Parsons, T. Phanh, K. S. Butcher, P. M. Desmond, B. M. Tress, P. G. Colman, B. R. Chambers, and S. M. Davis
Persistent Poststroke Hyperglycemia Is Independently Associated With Infarct Expansion and Worse Clinical Outcome
Stroke, September 1, 2003; 34(9): 2208 - 2214.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
R. Wan, S. Camandola, and M. P. Mattson
Intermittent Food Deprivation Improves Cardiovascular and Neuroendocrine Responses to Stress in Rats
J. Nutr., June 1, 2003; 133(6): 1921 - 1929.
[Abstract] [Full Text] [PDF]


Home page
Journal of Pharmacy PracticeHome page
J. C. Chappell and H. Cohen
Frontiers in Neuropharmacotherapy Part I: Alzheimer's Disease and Epilepsy
Journal of Pharmacy Practice, June 1, 2002; 15(3): 195 - 220.
[Abstract] [PDF]


Home page
StrokeHome page
T. A. Kent, V. M. Soukup, and R. H. Fabian
Heterogeneity Affecting Outcome From Acute Stroke Therapy: Making Reperfusion Worse
Stroke, October 1, 2001; 32(10): 2318 - 2327.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
H. J. Krugers, S. Maslam, J. Korf, M. Joels, and F. Holsboer
The Corticosterone Synthesis Inhibitor Metyrapone Prevents Hypoxia/Ischemia-Induced Loss of Synaptic Function in the Rat Hippocampus Editorial Comment
Stroke, May 1, 2000; 31(5): 1162 - 1172.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by AAN Enterprises, Inc.